
    
      This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, global study
      to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab
      monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC
      who are at high risk of recurrence after curative hepatic resection or ablation.
    
  